{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:27:16Z","timestamp":1789000036009,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11886-022-01753-x","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T14:02:45Z","timestamp":1658930565000},"page":"1261-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Update on Renal Sympathetic Denervation for the Treatment of Hypertension"],"prefix":"10.1007","volume":"24","author":[{"given":"Arundati","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-9193","authenticated-orcid":false,"given":"Namrata","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"1753_CR1","unstructured":"Collaborators GBDRF.\u00a0Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.\u00a02018;392(10159):1923\u20131994."},{"issue":"6","key":"1753_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"key":"1753_CR3","doi-asserted-by":"crossref","unstructured":"Group SR, et al.\u00a0A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u20132116.","DOI":"10.1056\/NEJMoa1511939"},{"issue":"6","key":"1753_CR4","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13\u2013115.","journal-title":"Hypertension"},{"issue":"6","key":"1753_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jch.13550","volume":"21","author":"SM Smith","year":"2019","unstructured":"Smith SM, et al. Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. J Clin Hypertens (Greenwich). 2019;21(6):825\u201334.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1753_CR6","doi-asserted-by":"crossref","unstructured":"Kirkland EB, et al.\u00a0Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003\u20132014. J Am Heart Assoc.\u00a02018;7(11).","DOI":"10.1161\/JAHA.118.008731"},{"issue":"12","key":"1753_CR7","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1097\/HJH.0000000000001502","volume":"35","author":"H Durand","year":"2017","unstructured":"Durand H, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346\u201357.","journal-title":"J Hypertens"},{"issue":"36","key":"1753_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.15585\/mmwr.mm6536e1","volume":"65","author":"M Ritchey","year":"2016","unstructured":"Ritchey M, et al. Vital signs: disparities in antihypertensive medication nonadherence among medicare part D beneficiaries - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(36):967\u201376.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"1753_CR9","doi-asserted-by":"publisher","first-page":"R1517","DOI":"10.1152\/ajpregu.2000.279.5.R1517","volume":"279","author":"GF DiBona","year":"2000","unstructured":"DiBona GF. Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2000;279(5):R1517\u201324.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"1753_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jacc.2014.03.059","volume":"64","author":"K Sakakura","year":"2014","unstructured":"Sakakura K, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635\u201343.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1753_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMc0904179","volume":"361","author":"MP Schlaich","year":"2009","unstructured":"Schlaich MP, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932\u20134.","journal-title":"N Engl J Med"},{"issue":"4 Pt 2","key":"1753_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.25.4.878","volume":"25","author":"VM Campese","year":"1995","unstructured":"Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 Pt 2):878\u201382.","journal-title":"Hypertension"},{"issue":"27","key":"1753_CR13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","volume":"327","author":"RL Converse Jr","year":"1992","unstructured":"Converse RL Jr, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"1753_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1113\/expphysiol.2014.080176","volume":"100","author":"CJ Barrett","year":"2015","unstructured":"Barrett CJ. Renal sympathetic nerves - what have they got to do with cardiovascular disease? Exp Physiol. 2015;100(4):359\u201365.","journal-title":"Exp Physiol"},{"issue":"2","key":"1753_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCINTERVENTIONS.112.000037","volume":"6","author":"A Myat","year":"2013","unstructured":"Myat A, et al. Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv. 2013;6(2):184\u201397.","journal-title":"Circ Cardiovasc Interv"},{"issue":"16","key":"1753_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1001\/jama.1953.03690160001001","volume":"152","author":"RH Smithwick","year":"1953","unstructured":"Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501\u20134.","journal-title":"J Am Med Assoc"},{"issue":"9917","key":"1753_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","volume":"383","author":"H Krum","year":"2014","unstructured":"Krum H, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622\u20139.","journal-title":"Lancet"},{"issue":"9756","key":"1753_CR18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"HTNI Symplicity","year":"2010","unstructured":"Symplicity HTNI, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903\u20139.","journal-title":"Lancet"},{"issue":"13","key":"1753_CR19","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jacc.2015.01.037","volume":"65","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"9981","key":"1753_CR20","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","volume":"385","author":"M Azizi","year":"2015","unstructured":"Azizi M, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957\u201365.","journal-title":"Lancet"},{"key":"1753_CR21","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Mahfoud F, et al.\u00a0Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474\u20133482. This is a prospective, open-label registry of 1742 high cardiovascular risk patients (treated with Symplicity Flex or Symplicity Spyral RF-RDN) that provides 3-year follow-up data on RDN, the largest and longest so far. This study demonstrates BP-lowering efficacy and procedural safety of RDN over the 3-year period.","DOI":"10.1093\/eurheartj\/ehz118"},{"issue":"9671","key":"1753_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275\u201381.","journal-title":"Lancet"},{"issue":"4","key":"1753_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","volume":"36","author":"DE Kandzari","year":"2015","unstructured":"Kandzari DE, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219\u201327.","journal-title":"Eur Heart J"},{"issue":"10137","key":"1753_CR24","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346\u201355.","journal-title":"Lancet"},{"issue":"10234","key":"1753_CR25","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M Bohm","year":"2020","unstructured":"Bohm M, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444\u201351.","journal-title":"Lancet"},{"issue":"10108","key":"1753_CR26","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"RR Townsend","year":"2017","unstructured":"Townsend RR, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160\u201370.","journal-title":"Lancet"},{"issue":"4","key":"1753_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcin.2019.10.061","volume":"13","author":"MA Weber","year":"2020","unstructured":"Weber MA, et al. The REDUCE HTN: REINFORCE: randomized, sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension. JACC Cardiovasc Interv. 2020;13(4):461\u201370.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10137","key":"1753_CR28","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"Azizi M, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335\u201345.","journal-title":"Lancet"},{"key":"1753_CR29","doi-asserted-by":"crossref","unstructured":"Azizi M, et al.\u00a0Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. Circulation.\u00a02019.","DOI":"10.1016\/S0735-1097(19)31641-9"},{"issue":"24","key":"1753_CR30","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/j.jcin.2020.09.054","volume":"13","author":"M Azizi","year":"2020","unstructured":"Azizi M, et al. 12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation. JACC Cardiovasc Interv. 2020;13(24):2922\u201333.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10293","key":"1753_CR31","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476\u201386.","journal-title":"Lancet"},{"issue":"2","key":"1753_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45(2):221\u201331.","journal-title":"Hypertens Res"},{"issue":"4","key":"1753_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2019.10.048","volume":"13","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, et al. Alcohol-mediated renal denervation using the Peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv. 2020;13(4):471\u201384.","journal-title":"JACC Cardiovasc Interv"},{"key":"1753_CR34","unstructured":"\u2022 Mahfoud F, et al.\u00a0Long-term results up to 12 months after catheter-based alcohol-mediated renal denervation for treatment of resistant hypertension. Circ Cardiovasc Interv.\u00a02021;14(9):e010075. This 3-arm randomized, single-blind trial in patients with resistant hypertension compares the safety and efficacy of (a) RF-RDN of the main renal artery, (b) RF-RDN of the main and distal arterial branches, or (c) US-RDN of the main renal artery. All 3 modalities lowered BP effectively; however, US-RDN performed better than RF-RDN in this study. The small sample size limits the reliability of the results."},{"issue":"5","key":"1753_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1161\/CIRCULATIONAHA.118.037654","volume":"139","author":"K Fengler","year":"2019","unstructured":"Fengler K, et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation. 2019;139(5):590\u2013600.","journal-title":"Circulation"},{"key":"1753_CR36","doi-asserted-by":"crossref","unstructured":"Pekarskiy SE, et al.\u00a0Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens.\u00a02017;35(2):369\u2013375.","DOI":"10.1097\/HJH.0000000000001160"},{"issue":"3","key":"1753_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/HYPERTENSIONAHA.116.08448","volume":"69","author":"P Gosse","year":"2017","unstructured":"Gosse P, et al. Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation: the DENERHTN study (renal denervation for hypertension). Hypertension. 2017;69(3):494\u2013500.","journal-title":"Hypertension"},{"issue":"23","key":"1753_CR38","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jcin.2021.09.020","volume":"14","author":"Y Ahmad","year":"2021","unstructured":"Ahmad Y, et al. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv. 2021;14(23):2614\u201324.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10333","key":"1753_CR39","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","volume":"399","author":"F Mahfoud","year":"2022","unstructured":"Mahfoud F, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401\u201310.","journal-title":"Lancet"},{"issue":"2","key":"1753_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ndt\/gfab154","volume":"37","author":"C Ott","year":"2022","unstructured":"Ott C, et al. Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years. Nephrol Dial Transplant. 2022;37(2):304\u201310.","journal-title":"Nephrol Dial Transplant"},{"key":"1753_CR41","doi-asserted-by":"crossref","unstructured":"Booth LC, et al.\u00a0Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension.\u00a02015;65(2):393\u2013400.","DOI":"10.1161\/HYPERTENSIONAHA.114.04176"},{"issue":"6","key":"1753_CR42","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1002\/ehf2.13655","volume":"8","author":"P Chen","year":"2021","unstructured":"Chen P, et al. The influence of inhibiting renal neural regeneration on the efficacy of renal denervation to chronic heart failure. ESC Heart Fail. 2021;8(6):4760\u201371.","journal-title":"ESC Heart Fail"},{"issue":"9","key":"1753_CR43","doi-asserted-by":"publisher","first-page":"R806","DOI":"10.1152\/ajpregu.00227.2014","volume":"310","author":"K Rodionova","year":"2016","unstructured":"Rodionova K, et al. Complex reinnervation pattern after unilateral renal denervation in rats. Am J Physiol Regul Integr Comp Physiol. 2016;310(9):R806\u201318.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"1753_CR44","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/ndt\/gfx088","volume":"32","author":"MF Sanders","year":"2017","unstructured":"Sanders MF, et al. Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(9):1440\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"16","key":"1753_CR45","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/eurheartj\/ehaa121","volume":"41","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41(16):1588\u201399.","journal-title":"Eur Heart J"},{"issue":"1","key":"1753_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","volume":"16","author":"RR Townsend","year":"2020","unstructured":"Townsend RR, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention. 2020;16(1):89\u201396.","journal-title":"EuroIntervention"},{"key":"1753_CR47","doi-asserted-by":"crossref","unstructured":"Schmieder RE.\u00a0Renal denervation: where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant.\u00a02020.","DOI":"10.1093\/ndt\/gfaa237"},{"issue":"1","key":"1753_CR48","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1080\/02656736.2021.1916100","volume":"38","author":"M Xia","year":"2021","unstructured":"Xia M, et al. Efficacy and safety of renal denervation for hypertension in patients with chronic kidney disease: a meta-analysis. Int J Hyperthermia. 2021;38(1):732\u201342.","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"1753_CR49","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40620-021-00966-7","volume":"34","author":"F Marin","year":"2021","unstructured":"Marin F, et al. Insights on safety and efficacy of renal artery denervation for uncontrolled-resistant hypertension in a high risk population with chronic kidney disease: first Italian real-world experience. J Nephrol. 2021;34(5):1445\u201355.","journal-title":"J Nephrol"},{"issue":"8","key":"1753_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jacc.2016.12.014","volume":"69","author":"RR Singh","year":"2017","unstructured":"Singh RR, et al. Catheter-based renal denervation exacerbates blood pressure fall during hemorrhage. J Am Coll Cardiol. 2017;69(8):951\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1753_CR51","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/ajh\/hpy108","volume":"31","author":"EK Chowdhury","year":"2018","unstructured":"Chowdhury EK, et al. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens. 2018;31(10):1156\u201363.","journal-title":"Am J Hypertens"},{"issue":"23","key":"1753_CR52","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.jacc.2021.04.044","volume":"77","author":"F Mahfoud","year":"2021","unstructured":"Mahfoud F, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol. 2021;77(23):2909\u201319.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1753_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J Vaclavik","year":"2011","unstructured":"Vaclavik J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069\u201375.","journal-title":"Hypertension"},{"issue":"10008","key":"1753_CR54","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368.","journal-title":"Lancet"},{"issue":"9","key":"1753_CR55","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/HJH.0000000000001025","volume":"34","author":"A Oliveras","year":"2016","unstructured":"Oliveras A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863\u201371.","journal-title":"J Hypertens"},{"key":"1753_CR56","doi-asserted-by":"crossref","unstructured":"Peixoto AJ.\u00a0Is there a role for device therapies in resistant hypertension?: The CON side. Kidney360.\u00a02020;1(1):9\u201313.","DOI":"10.34067\/KID.0000742019"},{"issue":"21","key":"1753_CR57","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.jacc.2018.08.2186","volume":"72","author":"TE Sharp 3rd","year":"2018","unstructured":"Sharp TE 3rd, et al. Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system. J Am Coll Cardiol. 2018;72(21):2609\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1753_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10741-020-09974-4","volume":"27","author":"H Fukuta","year":"2022","unstructured":"Fukuta H, et al. Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2022;27(1):29\u201336.","journal-title":"Heart Fail Rev"},{"issue":"9","key":"1753_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11886-021-01558-4","volume":"23","author":"A Younis","year":"2021","unstructured":"Younis A, Steinberg JS. Renal denervation for patients with atrial fibrillation. Curr Cardiol Rep. 2021;23(9):126.","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"1753_CR60","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jama.2019.21187","volume":"323","author":"JS Steinberg","year":"2020","unstructured":"Steinberg JS, et al. Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial. JAMA. 2020;323(3):248\u201355.","journal-title":"JAMA"},{"key":"1753_CR61","doi-asserted-by":"crossref","unstructured":"Nawar K, et al.\u00a0Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis. J Hum Hypertens.\u00a02022.","DOI":"10.1038\/s41371-022-00700-1"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-022-01753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-022-01753-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-022-01753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T23:09:43Z","timestamp":1665616183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-022-01753-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s11886-022-01753-x","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"19 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}